Immune thrombocytopenia

ITP · Rare Disease · 5 drugs · 6 indications

Autoimmune low platelet count.

Competitive Landscape (5 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
Ianalumab	NVS	BAFF receptor antagonist	Antibody	SC	PHASE3
Vyvgart	ARGX	FcRn Inhibitor	Antibody	IV / SC	APPROVED
Promacta	NVS	Thrombopoietin receptor agonist	Small molecule	Oral	APPROVED
Nplate	AMGN	Thrombopoietin receptor agonist	Fusion protein	SC	APPROVED
Doptelet	SOBI	Thrombopoietin receptor agonist	Small molecule	PO	APPROVED

Indications (6)

Immune thrombocytopenia (ITP)

Chronic immune thrombocytopenia (adult)

Doptelet APPROVED

Chronic immune thrombocytopenia (pediatric)

Doptelet APPROVED

Thrombocytopenia in chronic liver disease

Doptelet APPROVED

Chronic ITP

Promacta APPROVED

Immune thrombocytopenia

Ianalumab PHASE3Nplate APPROVED

Upcoming Catalysts

Vyvgart - Ocular MG - Ph3 - Topline (ADAPT-OCULUS)CLINICAL

ARGXQ1 2026

Vyvgart - oMG - Ph3 - Topline (ADAPT-OCULUS)CLINICAL

ARGX1Q26

Doptelet - Pediatric ITP + EU Expansion - OngoingCOMMERCIAL

SOBIH1 2026

Vyvgart - Myositis - Ph2/3 - Topline (ALKIVIA)CLINICAL

ARGXQ3 2026

Vyvgart - ITP - Ph3 - Topline (ADVANCE-NEXT)CLINICAL

ARGXQ4 2026

Vyvgart - AChR- gMG (Seronegative) - FDA Approval DecisionREGULATORY

ARGXBy end of 2026

Ianalumab - SLE - Ph3 - Topline (SIRIUS-SLE)CLINICAL

NVSH2 2026

Ianalumab - Sjogren's - Ph3 - ToplineCLINICAL

NVS2027

Vyvgart - Sjogren's Disease - Ph3 - ToplineCLINICAL

ARGXH2 2027

Data from Supabase · Updated 2026-03-24